Prices of widely used weight-loss drugs such as Wegovy and Ozempic are expected to drop significantly in India after the ...

Since 2021, the story of GLP-1s has illustrated that scientific progress is rarely a straight line from hypothesis to patient ...

The first daily GLP-1 pill for weight loss, oral semaglutide, marketed as Wegovy, was launched in the US last year, expanding access to obesity treatment beyond injections.

Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as ...

Obesity among adults and children in the US is still on the rise, despite the boom of weight-loss medications like Ozempic, a shocking new report released by the CDC has found.

Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Discover retatrutide's groundbreaking Phase 3 results: 28.7% average weight loss, knee pain relief, and potential to surpass ...

BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart ...

Retatrutide targets metabolism, appetite, and energy expenditure, promising impressive results. Clinical trials are being ...

This one-day decline has now brought NVO’s twelve-month return to -56%. The pertinent question: Is this a buying opportunity?

As Shreehas Tambe readies to take charge of the unified Biocon Group following the integration of Biocon Biologics, the company is entering what he calls a “capacity‑rich, demand‑heavy” phase—one ...